CLAIM CARD
The corpus provides limited evidence for mechanism-to-clinic translation because preclinical and mechanistic findings were not corroborated by matched human intervention data. Marinello 2025 demonstrated in a preclinical ovary model that epigenetic age tracked with ovarian reserve markers, yet no human trial in the corpus tested whether pharmacological rescue of ovarian aging alters clock readings. Pending further randomized trials, the use of epigenetic clocks as primary endpoints to guide anti-aging interventions or to market a proven standalone geroprotective intervention is not currently supported.
Evidence grade: exploratory
Contradiction status: none
Publication: 9e9f3163-3f3b-4c1f-9790-a8b1400b8696
Provenance: Derivation Web chain
Citation Support
source_1Bozack 2023source_2McGee 2024source_3Marinello 2025source_4Petersen 2021source_5Arpawong 2023